Literature DB >> 30498717

Maintenance with single agent bevacizumab fails to improve disease-control in metastatic colorectal cancer.

Susana Roselló1, Ricard Borrás1, Andrés Cervantes1.   

Abstract

Entities:  

Year:  2018        PMID： 30498717      PMCID： PMC6230839          DOI： 10.21037/hbsn.2018.08.02

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  9 in total

1.  Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

Authors:  Lieke H J Simkens; Harm van Tinteren; Anne May; Albert J ten Tije; Geert-Jan M Creemers; Olaf J L Loosveld; Felix E de Jongh; Frans L G Erdkamp; Zoran Erjavec; Adelheid M E van der Torren; Jolien Tol; Hans J J Braun; Peter Nieboer; Jacobus J M van der Hoeven; Janny G Haasjes; Rob L H Jansen; Jaap Wals; Annemieke Cats; Veerle A Derleyn; Aafke H Honkoop; Linda Mol; Cornelis J A Punt; Miriam Koopman
Journal:  Lancet       Date:  2015-04-07       Impact factor: 79.321

2.  First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

Authors:  Eduardo Díaz-Rubio; Auxiliadora Gómez-España; Bartomeu Massutí; Javier Sastre; Albert Abad; Manuel Valladares; Fernando Rivera; Maria J Safont; Purificación Martínez de Prado; Manuel Gallén; Encarnación González; Eugenio Marcuello; Manuel Benavides; Carlos Fernández-Martos; Ferrán Losa; Pilar Escudero; Antonio Arrivi; Andrés Cervantes; Rosario Dueñas; Amelia López-Ladrón; Adelaida Lacasta; Marta Llanos; Jose M Tabernero; Antonio Antón; Enrique Aranda
Journal:  Oncologist       Date:  2012-01-10

3.  Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).

Authors:  D Koeberle; D C Betticher; R von Moos; D Dietrich; P Brauchli; D Baertschi; K Matter; R Winterhalder; M Borner; S Anchisi; P Moosmann; A Kollar; P Saletti; A Roth; M Frueh; M Kueng; R A Popescu; S Schacher; V Hess; R Herrmann
Journal:  Ann Oncol       Date:  2015-01-20       Impact factor: 32.976

4.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

5.  Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

Authors:  Susanna Hegewisch-Becker; Ullrich Graeven; Christian A Lerchenmüller; Birgitta Killing; Reinhard Depenbusch; Claus-Christoph Steffens; Salah-Eddin Al-Batran; Thoralf Lange; Georg Dietrich; Jan Stoehlmacher; Andrea Tannapfel; Anke Reinacher-Schick; Julia Quidde; Tanja Trarbach; Axel Hinke; Hans-Joachim Schmoll; Dirk Arnold
Journal:  Lancet Oncol       Date:  2015-09-08       Impact factor: 41.316

Review 6.  Maintenance based Bevacizumab versus complete stop or continuous therapy after induction therapy in first line treatment of stage IV colorectal cancer: A meta-analysis of randomized clinical trials.

Authors:  Emiliano Tamburini; Britt Rudnas; Carlotta Santelmo; Fabrizio Drudi; Lorenzo Gianni; Stefania V L Nicoletti; Claudio Ridolfi; Davide Tassinari
Journal:  Crit Rev Oncol Hematol       Date:  2016-06-09       Impact factor: 6.312

7.  Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

Authors:  Thomas Aparicio; Francois Ghiringhelli; Valérie Boige; Karine Le Malicot; Julien Taieb; Olivier Bouché; Jean-Marc Phelip; Eric François; Christian Borel; Roger Faroux; Laetitia Dahan; Stéphane Jacquot; Dominique Genet; Faiza Khemissa; Etienne Suc; Françoise Desseigne; Patrick Texereau; Come Lepage; Jaafar Bennouna
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

8.  Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.

Authors:  Suayib Yalcin; Ruchan Uslu; Faysal Dane; Ugur Yilmaz; Nurullah Zengin; Evin Buyukunal; Suleyman Buyukberber; Celalettin Camci; Orhan Sencan; Sadettin Kilickap; Fatih Ozdener; Duygu Cevik
Journal:  Oncology       Date:  2013-11-12       Impact factor: 2.935

9.  Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.

Authors:  K K H Goey; S G Elias; H van Tinteren; M M Laclé; S M Willems; G J A Offerhaus; W W J de Leng; E Strengman; A J Ten Tije; G-J M Creemers; A van der Velden; F E de Jongh; F L G Erdkamp; B C Tanis; C J A Punt; M Koopman
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.